title: The Gothenburg MCI study: Design and distribution of Alzheimer's disease and subcortical vascular disease diagnoses from baseline to 6-year follow-up.
abstract: There is a need for increased nosological knowledge to enable rational trials in Alzheimer’s disease (AD) and related disorders. The ongoing Gothenburg mild cognitive impairment (MCI) study is an attempt to conduct longitudinal in-depth phenotyping of patients with different forms and degrees of cognitive impairment using neuropsychological, neuroimaging, and neurochemical tools. Particular attention is paid to the interplay between AD and subcortical vascular disease, the latter representing a disease entity that may cause or contribute to cognitive impairment with an effect size that may be comparable to AD. Of 664 patients enrolled between 1999 and 2013, 195 were diagnosed with subjective cognitive impairment (SCI), 274 with mild cognitive impairment (MCI), and 195 with dementia, at baseline. Of the 195 (29%) patients with dementia at baseline, 81 (42%) had AD, 27 (14%) SVD, 41 (21%) mixed type dementia (=AD + SVD = MixD), and 46 (23%) other etiologies. After 6 years, 292 SCI/MCI patients were eligible for follow-up. Of these 292, 69 (24%) had converted to dementia (29 (42%) AD, 16 (23%) SVD, 15 (22%) MixD, 9 (13%) other etiologies). The study has shown that it is possible to identify not only AD but also incipient and manifest MixD/SVD in a memory clinic setting. These conditions should be taken into account in clinical trials.
authors.forename: Anders
authors.initials: A
authors.lastname: Wallin
authors.forename: Arto
authors.initials: A
authors.lastname: Nordlund
authors.forename: Michael
authors.initials: M
authors.lastname: Jonsson
authors.forename: Karin
authors.initials: K
authors.lastname: Lind
authors.forename: Åke
authors.initials: Å
authors.lastname: Edman
authors.forename: Mattias
authors.initials: M
authors.lastname: Göthlin
authors.forename: Jacob
authors.initials: J
authors.lastname: Stålhammar
authors.forename: Marie
authors.initials: M
authors.lastname: Eckerström
authors.forename: Silke
authors.initials: S
authors.lastname: Kern
authors.forename: Anne
authors.initials: A
authors.lastname: Börjesson-Hanson
authors.forename: Mårten
authors.initials: M
authors.lastname: Carlsson
authors.forename: Erik
authors.initials: E
authors.lastname: Olsson
authors.forename: Henrik
authors.initials: H
authors.lastname: Zetterberg
authors.forename: Kaj
authors.initials: K
authors.lastname: Blennow
authors.forename: Johan
authors.initials: J
authors.lastname: Svensson
authors.forename: Annika
authors.initials: A
authors.lastname: Öhrfelt
authors.forename: Maria
authors.initials: M
authors.lastname: Bjerke
authors.forename: Sindre
authors.initials: S
authors.lastname: Rolstad
authors.forename: Carl
authors.initials: C
authors.lastname: Eckerström
mesh_terms: D000544:Alzheimer Disease / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology; D015415:Biomarkers / Q000097:blood / Q000134:cerebrospinal fluid; D000068456:Clinical Studies as Topic / Q000379:methods*; D015140:Dementia, Vascular / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D008279:Magnetic Resonance Imaging; D009483:Neuropsychological Tests; D012107:Research Design; D066127:White Matter / Q000473:pathology
chemical_list: D015415:Biomarkers